-
BioAlliance Pharma
- Chief Operating Officer
Paris
2008 - maintenant
Strategy and Medical Affairs
-
Urogene
- CEO
2004 - 2009
Chairman, CEO
Set up and implemented business strategy. Redesigned, implemented and speeded up the pre-clinical and clinical development programme of UG-058. Filed 4 key patents worldwide. Renegotiated licensing terms with partner.Licensed out one compound in phase II CT.
-
Molecular Engines Laboratories
- CEO
2002 - 2004
Chairman and Chief Executive Officer 2002 - 2004
Implemented a new management team,Modified business and R&D strategies, Started drug discovery and clinical trial programmes,Budget: 4M€ / year, 27 employees, Started the fund raising process and secured 7,5M€, Set up and implemented acquisition by Cerep
-
OSMO
- CEO
2000 - 2002
Chairman and Chief Executive Officer, Co-Founder
Set up the company,Implemented the organisational chart,
Implemented a network of more than 100 investigators in oncology,Turn Over: 1.2 M€ ( >10 clients, 8 major pharmaceutical companies,Headcount: 12 employees after 2 years of operations,Organised merger with Covidence, a German CRO (Turn Over: 17M€)
-
Synthelabo
- Head of clinical research department
1987 - 2000
SYNTHELABO 1987 – 2000
Licensing Director, General Manager 1998 - 2000
Responsible for medical and scientific evaluation of external projects (technologies and products), Opened new therapeutic areas (oncology, gastroenterology), Started discussions with major biotech companies for in-licensing products (preclinical phase)
Head of Clinical Research Department 1992 - 1998
Responsible for clinical development strategy and world-wide clinical operations phase I to phase IV (monitoring units, clinical trial management, data management, biostatistics, training, AQ, pharmacovigilance, finance and administration, Managed 18 different projects / year in 3 continents (USA, Europe and Japan), Budget: 30 - 45M€,Headcount: 250- 375 employees.
